The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Letter To The Editor

UCSD Moores EAB: A leak to The Cancer Letter derailed the iterative process

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Dear Editor, 

The UCSD Moores Cancer Center External Advisory Board is extremely disappointed in the commentary included in the most recent issue of The Cancer Letter regarding MCC (The Cancer Letter, June 2, 2023).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
EAB members, UCSD Moores Cancer Center
EAB members, UCSD Moores Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Byline
EAB members, UCSD Moores Cancer Center
EAB members, UCSD Moores Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account